A revolutionary pharmaceutical platform technology with anti-viral, anti-bacterial, anti-fungal and anti-inflammatory properties
Fulhold Pharma plc produces the patented CarboHydrate Derived Fulvic Acid (CHD-FA) and formulations containing this product. CHD-FA and its use provides a new pharmaceutical platform technology with wide applications in human and animal health.
We produce CHD-FA using a sustainable, environmentally-friendly technology, the process of which is also patented.
Its powerful broad-spectrum activity makes CHD-FA an effective agent in the fight against infection, including drug-resistant forms. Given its novel mechanism of action, the use of CHD-FA is advantageous as it prevents the use (and therefore over-use) of more specific but more limited spectrum antibiotics.
Founded as Ful Hold Ltd in 2002, Fulhold Pharma plc has a proven track record of the production and supply of pure CHD-FA together with a range formulated products using CHD-FA as the platform technology.
Fulhold Pharma Ltd is a UK-registered company which produces the patented CarboHydrate Derived Fulvic Acid (CHD-FA) and formulations containing this product. CHD-FA provides a new pharmaceutical platform technology with a wide range of applications in human and animal health. CHD-FA is a broad-spectrum anti-microbial/anti-inflammatory compound active on drug-resistant Gram positive, Gram negative, and fungal pathogens that can be both ingested and topically applied safely. This powerful antimicrobial activity makes CHD-FA an effective agent in the fight against infection, including drug-resistant forms, in human, animal health and oral health applications.
In addition, CHD-FA in combination with lower levels of antibiotics has demonstrated the same efficacy as higher levels of the same antibiotics alone. This has the potential in both human and animal health to reduce the quantity (and therefore over-use) of antibiotics being taken whilst retaining equal efficacy. This also presents opportunities to extend the life (and therefore patents) of antibiotics which are or are becoming ineffective due to drug-resistance.
Founded as Ful Hold Ltd in 2002, Fulhold Pharma Ltd has a proven track record of the production and supply of pure CHD-FA together with a range of formulated products using CHD-FA as the platform technology. We hold a range of patents for the manufacture and use of CHD-FA in human and animal health applications.
CHD-FA is a novel pharmaceutical platform technology and the base active ingredient in many current and planned formulations for the prevention or treatment of a wide variety of medical conditions.
CHD-FA is a safe, non-toxic, water soluble and heat stable ingredient that is manufactured to GMP standards. It is a new, pure, uniform version of an ancient natural ingredient – environmental fulvic acid. Environmental fulvic acid is derived from the microbial breakdown of plant and animal carbohydrate and has been present in the environment for millions of years.
CHD-FA, however, is a pure form of fulvic acid but without environmental contaminants such as heavy metals, herbicide and pesticide residues. It is therefore a safer and more effective form of fulvic acid than that sourced from the environment.
We produce CHD-FA using a sustainable, environmentally-friendly technology and currently have a manufacturing plants in Stellenbosch in South Africa and are analysing options for a second plant, potentially in the U.S. We have already proved that we can build a plant to the same standards and production capacity as the original manufacturing plant in less than 100 days.